Currently, dabrafenib (Tafinlar, FDA approved) and vemurafenib (Zelboraf, under clinical investigation with regard to LC) are the two drugs administered for the treatment of BRAF V600E-mutated NSCLC patients with metastatic disease [109]. Here, BRAF is linked to non-small cell lung carcinoma.